Figure 2.

Diverse release profiles of co-delivery. ai) Increased release of platinum (Pt) and daunorubicin (DRB) at pH 5.0 compared to release at pH 7.4. Reprinted²⁰ with permission from Elsevier. aii) Release of FITC-G-Ins triggered by glucose (Left). Release of cAMP triggered by glucose (Right). Reprinted²¹ with permission from The American Society. aiii) Increased release of CpG ODN and fluorescein in the presence of an enzyme, α-chymotrypsin. Reprinted²² with permission from American Chemical Society. bi) Modulating the release profile of BA and PPA based on the generation numbers. Reprinted²³ with permission from American Chemical Society. bii) Release from PLGA nanoparticles (Left) compared to sustained release of brimonidine and timolol maleate from PLGA nanoparticles-dendrimer hybrid (Right). Reprinted²⁴ with permission from American Chemical Society. biii) Spatially controlled release of DOX and Dtxl. Reprinted²⁵ with permission from John Wiley and Sons. ci) Staged release demonstrated by fast release of combrestatin and slow release of DOX. Reprinted²⁶ with permission from Nature Publishing Group. cii) Release of irinotecan and floxuridine at a constant synergistic 1:1 ratio for 25 hrs. Reprinted²⁷ with permission from Elsevier. ciii) Release of cytarabine and daunorubicin at a constant synergistic ratio of 5:1 in the plasma. Reprinted²⁸ with permission from Elsevier.